Who are Exjade's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Ferriprox, Desferal, Ferriprox (deferiprone), Captafer®, Deferiprone (DFP), deferiprone matching placebo tablets.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/deferasirox.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Exjade — Competitive Intelligence Brief

Exjade (DEFERASIROX) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Iron Chelator [EPC]. Area: Other.

marketed Iron Chelator [EPC] Flavin reductase (NADPH) Other Small molecule Live · refreshed every 30 min

Target snapshot

Exjade (DEFERASIROX) — Novartis. Exjade works by binding to iron in the body and removing it through the urine.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Exjade TARGET	DEFERASIROX	Novartis	marketed	Iron Chelator [EPC]	Flavin reductase (NADPH)	2005-01-01
Ferriprox	DEFERIPRONE	Chiesi	marketed	Iron Chelator [EPC]	Deoxyhypusine hydroxylase	2011-01-01
Desferal	DEFEROXAMINE	Mitem Pharma	marketed	Iron Chelator	Deoxyhypusine hydroxylase	1968-01-01
Ferriprox (deferiprone)	Ferriprox (deferiprone)	ApoPharma	marketed	Iron chelator	Ferric iron (Fe³⁺)
Captafer®	Captafer®	American University of Beirut Medical Center	marketed	Iron chelator	Ferric iron (Fe³⁺)
Deferiprone (DFP)	Deferiprone (DFP)	Azienda Ospedaliera V. Cervello	marketed	Iron chelator	Ferric iron (Fe³⁺)
deferiprone matching placebo tablets	deferiprone matching placebo tablets	ApoPharma	marketed	Iron chelator	Ferric iron (Fe³⁺)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Iron Chelator [EPC] class)

Chiesi · 1 drug in this class
Novartis · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Exjade — Competitive Intelligence Brief. https://druglandscape.com/ci/deferasirox. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab